Half of panelists on controversial new cholesterol guideline have current or recent ties to drug manufacturers

MeSH terms

• Cardiovascular Diseases / etiology
• Cardiovascular Diseases / prevention & control*
• Conflict of Interest*
• Drug Industry*
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
• Hypercholesterolemia / complications
• Hypercholesterolemia / drug therapy*
• Physicians / ethics*
• Practice Guidelines as Topic*